Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Angle Share News (AGL)
AGL Share
Price
AGL Share
News
AGL Share
Chat
AGL Share
Trades37
AGL
Live RNS
AGL Share
Charts
AGL Broker
Ratings
AGL Directors
Deals
AGL Financial
Diary
AGL
Fundamentals
AGL Short
Positions
AGL
Media
AGL Company
Research
AGL Company
Timeline
- There is currently no data for AGL
IN BRIEF: Angle highlights supportive data for DNA analysis tool
Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.
Current stock price: 17.85 pence, down 8.5% in London on Monday
12-month change: down 42%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Latest AGL News
- Angle's Parsortix Able To Predict Patients' Response To Treatment
14 Aug 2020 - IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix
20 Jul 2020 - Angle's 'Parsortix' advantageous in breast cancer in new research
20 Jul 2020 - Angle Progresses On Parsortix And De Novo Clearance From US Regulator
25 Jun 2020 - UK Earnings, Trading Statements Calendar - Next 7 Days
18 Jun 2020 - IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board
10 Jun 2020 - Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects
12 May 2020 - Angle upbeat on recent research using 'Parsortix'
12 May 2020
Related News
IN BRIEF: Angle names Peter Collins as interim CEO
(Alliance News) - Angle PLC - Guildford, England-based liquid biopsy company, which is to be renamed CelLBxHealth PLC - Appoints Peter Collins as inte...
Angle touts planned name and strategy change, Groen turns executive
(Alliance News) - Angle PLC shares fell on Wednesday, after it announced plans to rename itself CelLBxHealth PLC and "[pursue] a revised strategy", wi...
IN BRIEF: Angle CEO and finance lead step down after shareholder talks
Angle PLC - Guildford, England-based liquid biopsy company - Says that, following talks with an unnamed "significant shareholder", Chief Executive Off...
Angle News
Angle's Parsortix Able To Predict Patients' Response To Treatment
Angle's Parsortix Able To Predict Patients' Response To Treatment
IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix
IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix
Angle's 'Parsortix' advantageous in breast cancer in new research
(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertak...
Angle Progresses On Parsortix And De Novo Clearance From US Regulator
Angle Progresses On Parsortix And De Novo Clearance From US Regulator
UK Earnings, Trading Statements Calendar - Next 7 Days
UK Earnings, Trading Statements Calendar - Next 7 Days
IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board
IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board
Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects
Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects
Angle upbeat on recent research using 'Parsortix'
(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago ...
Follow the stocks
